SEC Form 4 · accession 0001209191-18-056072
PhaseBio Pharmaceuticals Inc · PHAS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Peter J Barris
10% Owner
M James Barrett
10% Owner
David M Mott
10% Owner
Patrick J Kerins
10% Owner
Scott D Sandell
10% Owner
Forest Baskett
10% Owner
NEW ENTERPRISE ASSOCIATES 13 LP
10% Owner
NEA 13 GP, Ltd
10% Owner
NEA Partners 13, Limited Partnership
10% Owner
Ravi Viswanathan
10% Owner
Period of report
Oct 22, 2018
Accepted (ET)
Oct 24, 2018 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001169245
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 22, 2018 | C | 4,841,634 | — | A | 4,841,634 | I | See Note 2 |
| Common StockF2 | Oct 22, 2018 | P | 1,800,000 | $5.00 | A | 6,641,634 | I | See Note 2 |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrants to Purchase Series B Preferred StockF2,F4 | $0.12 | Oct 22, 2018 | X | 49,030 | D | — | — | Series B Preferred Stock | 49,030 | 0 | I |
| Series B Preferred StockF2,F1 | — | Oct 22, 2018 | X | 49,030 | A | — | — | Common Stock | 49,030 | 3,280,804 | I |
| Series B Preferred StockF2,F1 | — | Oct 22, 2018 | S | 1,177 | D | — | — | Common Stock | 1,177 | 3,279,627 | I |
| Series B Preferred StockF2,F1 | — | Oct 22, 2018 | C | 3,279,627 | D | — | — | Common Stock | 3,279,627 | 0 | I |
| Warrants to Purchase Series C-1 Preferred StockF2,F4 | $0.12 | Oct 22, 2018 | X | 181,190 | D | — | — | Series C-1 Preferred Stock | 181,190 | 0 | I |
| Series C-1 Preferred StockF2,F1 | — | Oct 22, 2018 | X | 181,190 | A | — | — | Common Stock | 181,190 | 442,055 | I |
| Series C-1 Preferred StockF2,F1 | — | Oct 22, 2018 | S | 4,349 | D | — | — | Common Stock | 4,349 | 437,706 | I |
| Series C-1 Preferred StockF2,F1 | — | Oct 22, 2018 | C | 437,706 | D | — | — | Common Stock | 437,706 | 0 | I |
| Series D Preferred StockF2,F1 | — | Oct 22, 2018 | C | 1,124,301 | D | — | — | Common Stock | 1,124,301 | 0 | I |
Explanation of responses
- F1Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
- F2The securities are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and each of the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 13 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Patrick J. Kerins, David M. Mott, Scott D. Sandell and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 securities in which the Indirect Reporting Persons have no pecuniary interest.
- F3Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
- F4The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.